{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:25:30Z","timestamp":1771327530405,"version":"3.50.1"},"reference-count":175,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Monoamine oxidase (MAO) is an enzyme that catalyzes the deamination of\nmonoamines and other proteins. MAO\u2019s hyperactivation results in the massive generation of reactive\noxygen species, which leads to a variety of neurological diseases such as Alzheimer's disease,\nParkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and depression-like disorders.\nAlthough synthetic MAO inhibitors are clinically available, they are associated with side effects\nsuch as hepatotoxicity, cheese reaction, hypertensive crisis, and so on, necessitating the investigation\nof alternative MAO inhibitors from a natural source with a safe profile. Herbal medications\nhave a significant impact on the prevention of many diseases; additionally, they have fewer\nside effects and serve as a precursor for drug development. This review discusses the potential of\nherbal MAO inhibitors as well as their associated mechanism of action, with an aim to foster future\nresearch on herbal MAO inhibitors as a potential treatment for neurological diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450122666210707120256","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T03:53:06Z","timestamp":1625802786000},"page":"286-310","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Insights into the Mechanism of the Therapeutic Potential of Herbal\nMonoamine Oxidase Inhibitors in Neurological Diseases"],"prefix":"10.2174","volume":"23","author":[{"given":"Ashi","family":"Mannan","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":true,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Garg","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjot","family":"Kaur","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1021\/bi900413g","volume":"48","author":"Edmondson D.E.","year":"2009","unstructured":"Edmondson D.E.; Binda C.; Wang J.; Upadhyay A.K.; Mattevi A.; Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009,48(20),4220-4230","journal-title":"Biochemistry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fphar.2016.00340","volume":"7","author":"Finberg J.P.M.","year":"2016","unstructured":"Finberg J.P.M.; Rabey J.M.; Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front Pharmacol 2016,7,340","journal-title":"Front Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.2174\/0929867043364775","volume":"11","author":"Riederer P.","year":"2004","unstructured":"Riederer P.; Lachenmayer L.; Laux G.; Clinical applications of MAO-inhibitors. Curr Med Chem 2004,11(15),2033-2043","journal-title":"Curr Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"28322","DOI":"10.1074\/jbc.M111.241422","volume":"286","author":"Wang C.C.","year":"2011","unstructured":"Wang C.C.; Borchert A.; Ugun-Klusek A.; Tang L.Y.; Lui W.T.; Chu C.Y.; Billett E.; Kuhn H.; Ufer C.; Monoamine oxidase a expression is vital for embryonic brain development by modulating developmental apoptosis. J Biol Chem 2011,286(32),28322-28330","journal-title":"J Biol Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00702-018-1927-8","volume":"125","author":"Shih J.C.","year":"2018","unstructured":"Shih J.C.; Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy. J Neural Transm (Vienna) 2018,125(11),1553-1566","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"12684","DOI":"10.1073\/pnas.0505975102","volume":"102","author":"De Colibus L.","year":"2005","unstructured":"De Colibus L.; Li M.; Binda C.; Lustig A.; Edmondson D.E.; Mattevi A.; Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 2005,102(36),12684-12689","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1021\/bi051847g","volume":"45","author":"Li M.","year":"2006","unstructured":"Li M.; Binda C.; Mattevi A.; Edmondson D.E.; Functional role of the \u201caromatic cage\u201d in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. Biochemistry 2006,45(15),4775-4784","journal-title":"Biochemistry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(11)70141-7","volume":"10","author":"Kurian M.A.","year":"2011","unstructured":"Kurian M.A.; Gissen P.; Smith M.; Heales S.; Clayton P.T.; The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011,10(8),721-733","journal-title":"Lancet Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-211-33328-0_8","volume":"71","author":"Naoi M.","year":"2006","unstructured":"Naoi M.; Maruyama W.; Akao Y.; Yi H.; Yamaoka Y.; Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm Suppl 2006,71(71),67-77","journal-title":"J Neural Transm Suppl"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1021\/cb900264w","volume":"5","author":"Zheng H.","year":"2010","unstructured":"Zheng H.; Youdim M.B.; Fridkin M.; Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer\u2019s therapy. ACS Chem Biol 2010,5(6),603-610","journal-title":"ACS Chem Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1515\/BMC.2011.030","volume":"2","author":"Gaweska H.","year":"2011","unstructured":"Gaweska H.; Fitzpatrick P.F.; Structures and mechanism of the monoamine oxidase family. Biomol Concepts 2011,2(5),365-377","journal-title":"Biomol Concepts"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jmb.2004.02.032","volume":"338","author":"Ma J.","year":"2004","unstructured":"Ma J.; Yoshimura M.; Yamashita E.; Nakagawa A.; Ito A.; Tsukihara T.; Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J Mol Biol 2004,338(1),103-114","journal-title":"J Mol Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"9750","DOI":"10.1073\/pnas.1633804100","volume":"100","author":"Binda C.","year":"2003","unstructured":"Binda C.; Li M.; Hubalek F.; Restelli N.; Edmondson D.E.; Mattevi A.; Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 2003,100(17),9750-9755","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.molstruc.2005.09.026","volume":"785","author":"Alieva I.","year":"2006","unstructured":"Alieva I.; Mustafayeva N.; Gojayev N.; Conformation analysis of the N-terminal sequence Met1-Val60 of the tyrosine hydroxylase. J Mol Struct 2006,785,76-84","journal-title":"J Mol Struct"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/0024-3205(94)00388-2","volume":"55","author":"Youdim M.B.","year":"1994","unstructured":"Youdim M.B.; Lavie L.; Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson\u2019s disease. Life Sci 1994,55(25-26),2077-2082","journal-title":"Life Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"Youdim M.B.","year":"2006","unstructured":"Youdim M.B.; Bakhle Y.S.; Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 2006,147(Suppl. 1),S287-S296","journal-title":"Br J Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1006\/brcg.1995.1257","volume":"28","author":"Cummings J.L.","year":"1995","unstructured":"Cummings J.L.; Lewy body diseases with dementia: pathophysiology and treatment. Brain Cogn 1995,28(3),266-280","journal-title":"Brain Cogn"},{"key":"ref=18","first-page":"498","volume":"60","author":"Drozak J.","year":"2006","unstructured":"Drozak J.; Koz\u0142owski M.; [Monoamine oxidase as a target for drug action]. Postepy Hig Med Dosw 2006,60,498-515","journal-title":"Postepy Hig Med Dosw"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.nbd.2010.12.014","volume":"43","author":"Siddiqui A.","year":"2011","unstructured":"Siddiqui A.; Mallajosyula J.K.; Rane A.; Andersen J.K.; Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol Dis 2011,43(2),527-532","journal-title":"Neurobiol Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.mito.2021.03.009","volume":"58","author":"Singh S.","year":"2021","unstructured":"Singh S.; Singh T.G.; Rehni A.K.; Sharma V.; Singh M.; Kaur R.; Reviving mitochondrial bioenergetics: A relevant approach in epilepsy. Mitochondrion 2021,58,213-226","journal-title":"Mitochondrion"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-60761-756-3_1","volume":"648","author":"Gregersen N.","year":"2010","unstructured":"Gregersen N.; Bross P.; Protein misfolding and cellular stress: an overview. Methods Mol Biol 2010,648,3-23","journal-title":"Methods Mol Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e98878","DOI":"10.15252\/embj.201798878","volume":"37","author":"Kang S.S.","year":"2018","unstructured":"Kang S.S.; Ahn E.H.; Zhang Z.; Liu X.; Manfredsson F.P.; Sandoval I.M.; Dhakal S.; Iuvone P.M.; Cao X.; Ye K.; \u03b1-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson\u2019s disease. EMBO J 2018,37(12),e98878","journal-title":"EMBO J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.csbj.2019.12.013","volume":"18","author":"Poetsch A.R.","year":"2020","unstructured":"Poetsch A.R.; The genomics of oxidative DNA damage, repair, and resulting mutagenesis. Comput Struct Biotechnol J 2020,18,207-219","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.2174\/138161210793176572","volume":"16","author":"Agostinho P.","year":"2010","unstructured":"Agostinho P.; Cunha R.A.; Oliveira C.; Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer\u2019s disease. Curr Pharm Des 2010,16(25),2766-2778","journal-title":"Curr Pharm Des"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/jpet.116.237503","volume":"360","author":"Salim S.","year":"2017","unstructured":"Salim S.; Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther 2017,360(1),201-205","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"8416763","DOI":"10.1155\/2017\/8416763","volume":"2017","author":"Pizzino G.","year":"2017","unstructured":"Pizzino G.; Irrera N.; Cucinotta M.; Pallio G.; Mannino F.; Arcoraci V.; Squadrito F.; Altavilla D.; Bitto A.; Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev 2017,2017,8416763","journal-title":"Oxid Med Cell Longev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00210-010-0535-4","volume":"382","author":"Bielecka A.M.","year":"2010","unstructured":"Bielecka A.M.; Paul-Samojedny M.; Obuchowicz E.; Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol 2010,382(5-6),409-417","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"46338","DOI":"10.1038\/srep46338","volume":"7","author":"Lin Y.C.","year":"2017","unstructured":"Lin Y.C.; Chang Y.T.; Campbell M.; Lin T.P.; Pan C.C.; Lee H.C.; Shih J.C.; Chang P.C.; MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci Rep 2017,7,46338","journal-title":"Sci Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.neurobiolaging.2009.06.004","volume":"32","author":"Weinstock M.","year":"2011","unstructured":"Weinstock M.; Luques L.; Poltyrev T.; Bejar C.; Shoham S.; Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol Aging 2011,32(6),1069-1078","journal-title":"Neurobiol Aging"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.etp.2011.06.010","volume":"65","author":"Rodr\u00edguez S.","year":"2013","unstructured":"Rodr\u00edguez S.; Ito T.; He X.J.; Uchida K.; Nakayama H.; Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B. Exp Toxicol Pathol 2013,65(1-2),127-133","journal-title":"Exp Toxicol Pathol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1326-6-72","volume":"6","author":"Tapia-Gonz\u00e1lez S.","year":"2011","unstructured":"Tapia-Gonz\u00e1lez S.; Gir\u00e1ldez-P\u00e9rez R.M.; Cuartero M.I.; Casarejos M.J.; Mena M.\u00c1.; Wang X.F.; S\u00e1nchez-Capelo A.; Dopamine and \u03b1-synuclein dysfunction in Smad3 null mice. Mol Neurodegener 2011,6,72","journal-title":"Mol Neurodegener"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"135754","DOI":"10.1016\/j.neulet.2021.135754","volume":"749","author":"Sharma T.","year":"2021","unstructured":"Sharma T.; Kaur D.; Grewal A.K.; Singh T.G.; Therapies modulating insulin resistance in Parkinson\u2019s disease: A cross talk. Neurosci Lett 2021,749,135754","journal-title":"Neurosci Lett"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"110373","DOI":"10.1016\/j.biopha.2020.110373","volume":"129","author":"Sharma V","year":"2020","unstructured":"Sharma V; Kaur A; Singh TG; Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease. Biomed Pharmacother 2020,129,110373","journal-title":"Biomed Pharmacother"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12640-017-9824-8","volume":"33","author":"W\u0105sik A.","year":"2018","unstructured":"W\u0105sik A.; Roma\u0144ska I.; Zelek-Molik A.; Antkiewicz-Michaluk L.; Multiple administration of endogenous amines TIQ and 1MeTIQ protects against a 6-OHDA-induced essential fall of dopamine release in the rat striatum: In vivo microdialysis study. Neurotox Res 2018,33(3),523-531","journal-title":"Neurotox Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/j.1471-4159.2007.05115.x","volume":"104","author":"Gomez-Lazaro M.","year":"2008","unstructured":"Gomez-Lazaro M.; Galindo M.F.; Concannon C.G.; Segura M.F.; Fernandez-Gomez F.J.; Llecha N.; Comella J.X.; Prehn J.H.; Jordan J.; 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J Neurochem 2008,104(6),1599-1612","journal-title":"J Neurochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-161088","volume":"57","author":"T\u00f6nnies E.","year":"2017","unstructured":"T\u00f6nnies E.; Trushina E.; Oxidative Stress, Synaptic Dysfunction, and\u00a0Alzheimer\u2019s Disease. J Alzheimers Dis 2017,57(4),1105-1121","journal-title":"J Alzheimers Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41556-018-0133-0","volume":"20","author":"Eisner V.","year":"2018","unstructured":"Eisner V.; Picard M.; Hajn\u00f3czky G.; Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat Cell Biol 2018,20(7),755-765","journal-title":"Nat Cell Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1155\/2015\/151979","volume":"2015","author":"Alavi Naini S.M.","year":"2015","unstructured":"Alavi Naini S.M.; Soussi-Yanicostas N.; Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev 2015,2015,151979","journal-title":"Oxid Med Cell Longev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.117.241653","volume":"362","author":"Borroni E.","year":"2017","unstructured":"Borroni E.; Bohrmann B.; Grueninger F.; Prinssen E.; Nave S.; Loetscher H.; Chinta S.J.; Rajagopalan S.; Rane A.; Siddiqui A.; Ellenbroek B.; Messer J.; P\u00e4hler A.; Andersen J.K.; Wyler R.; Cesura A.M.; Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer\u2019s Disease. J Pharmacol Exp Ther 2017,362(3),413-423","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1152\/physrev.00011.2017","volume":"98","author":"Fricker M.","year":"2018","unstructured":"Fricker M.; Tolkovsky A.M.; Borutaite V.; Coleman M.; Brown G.C.; Neuronal Cell Death. Physiol Rev 2018,98(2),813-880","journal-title":"Physiol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"8590578","DOI":"10.1155\/2016\/8590578","volume":"2016","author":"Manoharan S.","year":"2016","unstructured":"Manoharan S.; Guillemin G.J.; Abiramasundari R.S.; Essa M.M.; Akbar M.; Akbar M.D.; The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Huntington\u2019s Disease: A Mini Review. Oxid Med Cell Longev 2016,2016,8590578","journal-title":"Oxid Med Cell Longev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00210-009-0476-y","volume":"381","author":"Rehni A.K.","year":"2010","unstructured":"Rehni A.K.; Singh T.G.; Singh N.; Arora S.; Tramadol-induced seizurogenic effect: a possible role of opioid-dependent histamine H1 receptor activation-linked mechanism. Naunyn Schmiedebergs Arch Pharmacol 2010,381(1),11-19","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/157015909787602823","volume":"7","author":"Uttara B.","year":"2009","unstructured":"Uttara B.; Singh A.V.; Zamboni P.; Mahajan R.T.; Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009,7(1),65-74","journal-title":"Curr Neuropharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"118401","DOI":"10.1016\/j.lfs.2020.118401","volume":"262","author":"Sharma V.K.","year":"2020","unstructured":"Sharma V.K.; Singh T.G.; Insulin resistance and bioenergetic manifestations: Targets and approaches in Alzheimer\u2019s disease. Life Sci 2020,262,118401","journal-title":"Life Sci"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1389450120666191017114735","volume":"21","author":"Sharma VK","year":"2020","unstructured":"Sharma VK; Singh TG; Navigating Alzheimer\u2019s disease via Chronic Stress: The Role of Glucocorticoids. Curr Drug Targets 2020,21(5),433-444","journal-title":"Curr Drug Targets"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2174\/1570159X18666200128125641","volume":"18","author":"Sharma VK","year":"2020","unstructured":"Sharma VK; Mehta V; Singh TG; Alzheimer\u2019s disorder: Epigenetic connection and associated risk factors. Curr Neuropharmacol 2020,18(8),740-753","journal-title":"Curr Neuropharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fnins.2018.00419","volume":"12","author":"Quartey M.O.","year":"2018","unstructured":"Quartey M.O.; Nyarko J.N.K.; Pennington P.R.; Heistad R.M.; Klassen P.C.; Baker G.B.; Mousseau D.D.; Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A\/B in the Hippocampus, but Not in the Cortex. Front Neurosci 2018,12,419","journal-title":"Front Neurosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","volume":"9","author":"Cai Z.","year":"2014","unstructured":"Cai Z.; Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer\u2019s disease (Review). Mol Med Rep 2014,9(5),1533-1541","journal-title":"Mol Med Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF03324240","volume":"6","author":"Parnetti L.","year":"1994","unstructured":"Parnetti L.; Reboldi G.P.; Santucci C.; Santucci A.; Gaiti A.; Brunetti M.; Cecchetti R.; Senin U.; Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging (Milano) 1994,6(3),201-207","journal-title":"Aging (Milano)"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8954201","volume":"2019","author":"Sturza A","year":"2019","unstructured":"Sturza A; Popoiu CM; Ionic\u0103 M; Duicu OM; Olariu S; Muntean DM; Boia ES; Monoamine oxidase-related vascular oxidative stress in diseases associated with inflammatory burden. Oxid Med Cell Longev 2019,2019","journal-title":"Oxid Med Cell Longev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5607\/en.2013.22.1.1","volume":"22","author":"Youdim M.B.","year":"2013","unstructured":"Youdim M.B.; Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol 2013,22(1),1-10","journal-title":"Exp Neurobiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"O\u2019Brien R.J.","year":"2011","unstructured":"O\u2019Brien R.J.; Wong P.C.; Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci 2011,34,185-204","journal-title":"Annu Rev Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.lfs.2018.06.025","volume":"207","author":"Wenzel T.J.","year":"2018","unstructured":"Wenzel T.J.; Klegeris A.; Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer\u2019s disease. Life Sci 2018,207,314-322","journal-title":"Life Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/molecules23020250","volume":"23","author":"Stefanachi A.","year":"2018","unstructured":"Stefanachi A.; Leonetti F.; Pisani L.; Catto M.; Carotti A.; Coumarin: A natural, privileged and versatile scaffold for bioactive compounds. Molecules 2018,23(2),250","journal-title":"Molecules"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-3-7091-6301-6_10","volume":"60","author":"Weinstock M.","year":"2000","unstructured":"Weinstock M.; Bejar C.; Wang R.H.; Poltyrev T.; Gross A.; Finberg J.P.; Youdim M.B.; TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease. J Neural Transm Suppl 2000,60(60),157-169","journal-title":"J Neural Transm Suppl"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1021\/acschemneuro.8b00220","volume":"10","author":"Kumar B.","year":"2019","unstructured":"Kumar B.; Dwivedi A.R.; Sarkar B.; Gupta S.K.; Krishnamurthy S.; Mantha A.K.; Parkash J.; Kumar V.; 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer\u2019s Disease. ACS Chem Neurosci 2019,10(1),252-265","journal-title":"ACS Chem Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13195-017-0279-1","volume":"9","author":"Schedin-Weiss S.","year":"2017","unstructured":"Schedin-Weiss S.; Inoue M.; Hromadkova L.; Teranishi Y.; Yamamoto N.G.; Wiehager B.; Bogdanovic N.; Winblad B.; Sandebring-Matton A.; Frykman S.; Tjernberg L.O.; Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \u03b3-secretase and regulates neuronal amyloid \u03b2-peptide levels. Alzheimers Res Ther 2017,9(1),57","journal-title":"Alzheimers Res Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1471-4159.2006.04258.x","volume":"100","author":"Avramovich-Tirosh Y.","year":"2007","unstructured":"Avramovich-Tirosh Y.; Amit T.; Bar-Am O.; Zheng H.; Fridkin M.; Youdim M.B.; Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer\u2019s disease. J Neurochem 2007,100(2),490-502","journal-title":"J Neurochem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"eaav0316","DOI":"10.1126\/sciadv.aav0316","volume":"5","author":"Park J.H.","year":"2019","unstructured":"Park J.H.; Ju Y.H.; Choi J.W.; Song H.J.; Jang B.K.; Woo J.; Chun H.; Kim H.J.; Shin S.J.; Yarishkin O.; Jo S.; Park M.; Yeon S.K.; Kim S.; Kim J.; Nam M.H.; Londhe A.M.; Kim J.; Cho S.J.; Cho S.; Lee C.; Hwang S.Y.; Kim S.W.; Oh S.J.; Cho J.; Pae A.N.; Lee C.J.; Park K.D.; Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer\u2019s disease. Sci Adv 2019,5(3),eaav0316","journal-title":"Sci Adv"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Halliday G.M.; Brundin P.; Volkmann J.; Schrag A.E.; Lang A.E.; Parkinson disease. Nat Rev Dis Primers 2017,3,17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1","author":"Kouli A.","year":"2018","unstructured":"Kouli A.; Torsney K.M.; Kuan W.L.;  Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects 2018","journal-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects"},{"key":"ref=62","author":"Eckert L.L.","year":"2012","unstructured":"Eckert L.L.;  Parkinson's disease and a dopamine-derived neurotoxin, 3,4-Dihydroxyphenylacetaldehyde : Implications for proteins, microglia, and neurons 2012","journal-title":"Parkinson's disease and a dopamine-derived neurotoxin, 3,4-Dihydroxyphenylacetaldehyde : Implications for proteins, microglia, and neurons"},{"key":"ref=63","volume":"2","author":"Ayano G.","year":"2016","unstructured":"Ayano G.; Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures. J Mental Dis Treatment 2016,2(2)","journal-title":"J Mental Dis Treatment"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.nurt.2008.10.035","volume":"6","author":"Petzer J.P.","year":"2009","unstructured":"Petzer J.P.; Castagnoli N.; Schwarzschild M.A.; Chen J.F.; Van der Schyf C.J.; Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson\u2019s disease. Neurotherapeutics 2009,6(1),141-151","journal-title":"Neurotherapeutics"},{"key":"ref=65","first-page":"190579","volume":"6","author":"Nam MH","year":"2020","unstructured":"Nam MH; Park JH; Song HJ; Choi JW; Kim S; KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson\u2019s disease. bioRevix 2020,6,190579","journal-title":"bioRevix"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00702-017-1709-8","volume":"125","author":"Naoi M.","year":"2018","unstructured":"Naoi M.; Maruyama W.; Shamoto-Nagai M.; Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis. J Neural Transm (Vienna) 2018,125(1),53-66","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","volume":"27","author":"Ulrich S.","year":"2017","unstructured":"Ulrich S.; Ricken R.; Adli M.; Tranylcypromine in mind (Part I): Review of pharmacology. Eur Neuropsychopharmacol 2017,27(8),697-713","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euroneuro.2017.04.003","volume":"27","author":"Ricken R.","year":"2017","unstructured":"Ricken R.; Ulrich S.; Schlattmann P.; Adli M.; Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol 2017,27(8),714-731","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=69","first-page":"393","volume":"5","author":"Knoll J.","year":"1972","unstructured":"Knoll J.; Magyar K.; Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972,5,393-408","journal-title":"Adv Biochem Psychopharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1747-4949.2009.00387.x","volume":"4","author":"Allen C.L.","year":"2009","unstructured":"Allen C.L.; Bayraktutan U.; Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009,4(6),461-470","journal-title":"Int J Stroke"},{"key":"ref=71","first-page":"3772","volume":"20","author":"Grewal A.K.","year":"2020","unstructured":"Grewal A.K.; Singh T.G.; Singh N.; Potential Herbal Drugs For Ischemic Stroke: A Review. Plant Arch 2020,20(1),3772-3783","journal-title":"Plant Arch"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"25959","DOI":"10.3390\/ijms161125939","volume":"16","author":"Falkowska A.","year":"2015","unstructured":"Falkowska A.; Gutowska I.; Goschorska M.; Nowacki P.; Chlubek D.; Baranowska-Bosiacka I.; Energy metabolism of the brain, including the cooperation between astrocytes and neurons, especially in the context of glycogen metabolism. Int J Mol Sci 2015,16(11),25959-25981","journal-title":"Int J Mol Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/glia.20423","volume":"54","author":"Kimelberg H.K.","year":"2006","unstructured":"Kimelberg H.K.; Macvicar B.A.; Sontheimer H.; Anion channels in astrocytes: biophysics, pharmacology, and function. Glia 2006,54(7),747-757","journal-title":"Glia"},{"key":"ref=74","author":"Grewal AK","unstructured":"Grewal AK; Singh N; Singh TG; Effects of Resveratrol Postconditioning on Cerebral Ischemia in mice: Role of the Sirtuin-1 (SIRT1) Pathway. Can J Physiol Pharmacol 2019; 97(11): 1094-1101."},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1248\/bpb.23.406","volume":"23","author":"Kato M.","year":"2000","unstructured":"Kato M.; Iwata H.; Okamoto M.; Ishii T.; Narita H.; Focal cerebral ischemia-induced escape deficit in rats is ameliorated by a reversible inhibitor of monoamine oxidase-a: implications for a novel animal model of post-stroke depression. Biol Pharm Bull 2000,23(4),406-410","journal-title":"Biol Pharm Bull"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12035-019-01788-2","volume":"57","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Feng S.; Subedi K.; Wang H.; Attenuation of ischemic stroke-caused brain injury by a monoamine oxidase inhibitor involves improved proteostasis and reduced neuroinflammation. Mol Neurobiol 2020,57(2),937-948","journal-title":"Mol Neurobiol"},{"key":"ref=77","author":"Chand SP","year":"2020","unstructured":"Chand SP; Marwaha R;  Anxiety 2020","journal-title":"Anxiety"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","volume":"19","author":"Bandelow B.","year":"2017","unstructured":"Bandelow B.; Michaelis S.; Wedekind D.; Treatment of anxiety disorders. Dialogues Clin Neurosci 2017,19(2),93-107","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=79","first-page":"10","volume":"26","author":"Madhav M.","year":"2001","unstructured":"Madhav M.; Epidemiological study of prevalence of mental disorders in India. Indian J Community Med 2001,26(4),10-12","journal-title":"Indian J Community Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.31887\/DCNS.2017.19.2\/rparikh","volume":"19","author":"Khambaty M.","year":"2017","unstructured":"Khambaty M.; Parikh R.M.; Cultural aspects of anxiety disorders in India. Dialogues Clin Neurosci 2017,19(2),117-126","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fnhum.2013.00203","volume":"7","author":"Robinson O.J.","year":"2013","unstructured":"Robinson O.J.; Vytal K.; Cornwell B.R.; Grillon C.; The impact of anxiety upon cognition: perspectives from human threat of shock studies. Front Hum Neurosci 2013,7,203","journal-title":"Front Hum Neurosci"},{"key":"ref=82","first-page":"30","volume":"38","author":"Bystritsky A.","year":"2013","unstructured":"Bystritsky A.; Khalsa S.S.; Cameron M.E.; Schiffman J.; Current diagnosis and treatment of anxiety disorders. P 2013,38(1),30-57","journal-title":"P"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1515\/REVNEURO.2010.21.2.119","volume":"21","author":"Nikolaus S.","year":"2010","unstructured":"Nikolaus S.; Antke C.; Beu M.; M\u00fcller H.W.; Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies. Rev Neurosci 2010,21(2),119-139","journal-title":"Rev Neurosci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1211\/0022357001774075","volume":"52","author":"Sloley B.D.","year":"2000","unstructured":"Sloley B.D.; Urichuk L.J.; Morley P.; Durkin J.; Shan J.J.; Pang P.K.; Coutts R.T.; Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol 2000,52(4),451-459","journal-title":"J Pharm Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1021\/acs.jafc.6b01707","volume":"64","author":"Guo B.","year":"2016","unstructured":"Guo B.; Zheng C.; Cai W.; Cheng J.; Wang H.; Li H.; Sun Y.; Cui W.; Wang Y.; Han Y.; Lee S.M.; Zhang Z.; Multifunction of Chrysin in Parkinson\u2019s Model: Anti-Neuronal Apoptosis, Neuroprotection via Activation of MEF2D, and Inhibition of Monoamine Oxidase-B. J Agric Food Chem 2016,64(26),5324-5333","journal-title":"J Agric Food Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e22146","DOI":"10.1002\/syn.22146","volume":"74","author":"Xiao B.","year":"2020","unstructured":"Xiao B.; Han F.; Shi Y.; Administration of moclobemide facilitates fear extinction and attenuates anxiety-like behaviors by regulating synaptic-associated proteins in a rat model of post-traumatic stress disorder. Synapse 2020,74(6),e22146","journal-title":"Synapse"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jep.2017.07.005","volume":"208","author":"Ma J.","year":"2017","unstructured":"Ma J.; Wang F.; Yang J.; Dong Y.; Su G.; Zhang K.; Pan X.; Ma P.; Zhou T.; Wu C.; Xiaochaihutang attenuates depressive\/anxiety-like behaviors of social isolation-reared mice by regulating monoaminergic system, neurogenesis and BDNF expression. J Ethnopharmacol 2017,208,94-104","journal-title":"J Ethnopharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/2152-7806.169561","volume":"6","author":"Zarei S.","year":"2015","unstructured":"Zarei S.; Carr K.; Reiley L.; Diaz K.; Guerra O.; Altamirano P.F.; Pagani W.; Lodin D.; Orozco G.; Chinea A.; A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 2015,6,171","journal-title":"Surg Neurol Int"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/bmb\/ldw026","volume":"119","author":"Morgan S.","year":"2016","unstructured":"Morgan S.; Orrell R.W.; Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull 2016,119(1),87-98","journal-title":"Br Med Bull"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fnins.2018.00185","volume":"12","author":"Vermeiren Y.","year":"2018","unstructured":"Vermeiren Y.; Janssens J.; Van Dam D.; De Deyn P.P.; Serotonergic dysfunction in amyotrophic lateral sclerosis and parkinson\u2019s disease: Similar mechanisms, dissimilar outcomes. Front Neurosci 2018,12,185","journal-title":"Front Neurosci"},{"key":"ref=91","first-page":"1385","volume":"19","author":"Arti A.K.","year":"2019","unstructured":"Arti A.K.; Singh M.; Arora S.; Dhiman S.; Satija S.; Singh T.G.; Pharmacotherapy Of Amyotrophic Lateral Sclerosis: An Insight. Plant Arch 2019,19(2),1385-1397","journal-title":"Plant Arch"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.31887\/DCNS.2016.18.1\/pnopoulos","volume":"18","author":"Nopoulos P.C.","year":"2016","unstructured":"Nopoulos P.C.; Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci 2016,18(1),91-98","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=93","author":"Ajitkumar A","year":"2020","unstructured":"Ajitkumar A; De Jesus O.;  Huntington Disease 2020","journal-title":"Huntington Disease"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666201109090824","author":"Vishwas S.","year":"2020","unstructured":"Vishwas S.; Gulati M.; Kapoor B.; Gupta S.; Singh S.K.; Awasthi A.; Khan A.; Goyal A.; Bansal A.; Baishnab S.; Singh T.G.; Arora S.; Porwal O.; Kumar A.; Kumar V.; Expanding the arsenal against Huntington\u2019s disease- Herbal drugs and their nanoformulations. Curr Neuropharmacol 2020","journal-title":"Curr Neuropharmacol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s12035-014-8974-4","volume":"52","author":"Ooi J.","year":"2015","unstructured":"Ooi J.; Hayden M.R.; Pouladi M.A.; Inhibition of Excessive Monoamine Oxidase A\/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Mol Neurobiol 2015,52(3),1850-1861","journal-title":"Mol Neurobiol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fnins.2013.00114","volume":"7","author":"Chen J.Y.","year":"2013","unstructured":"Chen J.Y.; Wang E.A.; Cepeda C.; Levine M.S.; Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci 2013,7,114","journal-title":"Front Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00702-003-0103-x","volume":"111","author":"Markianos M.","year":"2004","unstructured":"Markianos M.; Panas M.; Kalfakis N.; Vassilopoulos D.; Platelet monoamine oxidase activity in subjects tested for Huntington\u2019s disease gene mutation. J Neural Transm (Vienna) 2004,111(4),475-483","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.expneurol.2016.01.019","volume":"278","author":"Garcia-Miralles M.","year":"2016","unstructured":"Garcia-Miralles M.; Ooi J.; Ferrari Bardile C.; Tan L.J.; George M.; Drum C.L.; Lin R.Y.; Hayden M.R.; Pouladi M.A.; Pouladi M.A.; Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Exp Neurol 2016,278,4-10","journal-title":"Exp Neurol"},{"key":"ref=99","author":"Sidhu G","year":"2020","unstructured":"Sidhu G; Marwaha R.;  Phenelzine 2020","journal-title":"Phenelzine"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.ajp-rj.2020.150402","volume":"15","author":"Kiani C.","year":"2020","unstructured":"Kiani C.; Tranylcypromine: its pharmacology, safety, and efficacy. Am J Psychiatry Resid J 2020,15,3-5","journal-title":"Am J Psychiatry Resid J"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00702-020-02142-w","volume":"127","author":"Finberg J.P.M.","year":"2020","unstructured":"Finberg J.P.M.; The discovery and development of rasagiline as a new anti-Parkinson medication. J Neural Transm (Vienna) 2020,127(2),125-130","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=102","first-page":"579","volume":"4","author":"Thull U.","year":"1998","unstructured":"Thull U.; Carrupt P-A.; Testa B.; Pargyline Analogues as Potent, Non-selective Monoamine Oxidase Inhibitors. Pharm Pharmacol Commun 1998,4,579-581","journal-title":"Pharm Pharmacol Commun"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/17425255.2017.1273901","volume":"13","author":"Riederer P.","year":"2017","unstructured":"Riederer P.; M\u00fcller T.; Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol 2017,13(2),233-240","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4062\/biomolther.2012.100","volume":"21","author":"Kim J.H.","year":"2013","unstructured":"Kim J.H.; Son Y.K.; Kim G.H.; Hwang K.H.; Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K. Biomol Ther (Seoul) 2013,21(3),234-240","journal-title":"Biomol Ther (Seoul)"},{"key":"ref=105","first-page":"437","volume":"3","author":"Gaur K.","year":"2017","unstructured":"Gaur K.; Sharma B.; Antidepressants: mechanism of action, toxicity and possible amelioration. J Appl Biotechnol Bioeng 2017,3,437-448","journal-title":"J Appl Biotechnol Bioeng"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138945012799499794","volume":"13","author":"Weinreb O.","year":"2012","unstructured":"Weinreb O.; Amit T.; Bar-Am O.; Youdim M.B.; Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer\u2019s disease treatment. Curr Drug Targets 2012,13(4),483-494","journal-title":"Curr Drug Targets"},{"key":"ref=107","first-page":"389","volume":"31","author":"Wang Y.","year":"2016","unstructured":"Wang Y.; Sun Y.; Guo Y.; Wang Z.; Huang L.; Li X.; Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer\u2019s disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives. J Enzyme Inhib Med Chem 2016,31(3),389-397","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/bph.13318","volume":"173","author":"Weinreb O.","year":"2016","unstructured":"Weinreb O.; Amit T.; Bar-Am O.; Youdim M.B.; Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and \u03b2-amyloid in ageing and Alzheimer\u2019s disease. Br J Pharmacol 2016,173(13),2080-2094","journal-title":"Br J Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3390\/molecules24040810","volume":"24","author":"Chaurasiya N.D.","year":"2019","unstructured":"Chaurasiya N.D.; Zhao J.; Pandey P.; Doerksen R.J.; Muhammad I.; Tekwani B.L.; Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). Molecules 2019,24(4),810","journal-title":"Molecules"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1527-3458.2003.tb00245.x","volume":"9","author":"Bonnet U.","year":"2003","unstructured":"Bonnet U.; Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003,9(1),97-140","journal-title":"CNS Drug Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"15976","DOI":"10.3390\/molecules200915976","volume":"20","author":"Khattab S.N.","year":"2015","unstructured":"Khattab S.N.; Khalil H.H.; Bekhit A.A.; El-Rahman M.M.; El-Faham A.; Albericio F.; Synthesis and Preliminary Biological Evaluation of 1,3,5-Triazine Amino Acid Derivatives to Study Their MAO Inhibitors. Molecules 2015,20(9),15976-15988","journal-title":"Molecules"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/neu.2020.6","volume":"32","author":"Williams T.","year":"2020","unstructured":"Williams T.; McCaul M.; Schwarzer G.; Cipriani A.; Stein D.J.; Ipser J.; Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis. Acta Neuropsychiatr 2020,32(4),169-176","journal-title":"Acta Neuropsychiatr"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0223-5234(92)90026-W","volume":"27","author":"Moureau F.","year":"1992","unstructured":"Moureau F.; Wouters J.; Vercauteren D.P.; Collin S.; Evrard G.; Durant F.; Ducrey F.; Koenig J.J.; Jarreau F.X.; A reversible monoamine oxidase inhibitor, toloxatone: structural, and electronic properties. Eur J Med Chem 1992,27,939-948","journal-title":"Eur J Med Chem"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4236\/ojd.2017.62004","volume":"6","author":"Entzeroth M","year":"2017","unstructured":"Entzeroth M; Ratty AK; Monoamine Oxidase Inhibitors: revisiting a therapeutic principle. OJD 2017,6,31-68","journal-title":"OJD"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3389\/fphar.2019.01590","volume":"10","author":"Reyes-Parada M.","year":"2020","unstructured":"Reyes-Parada M.; Iturriaga-Vasquez P.; Cassels B.K.; Amphetamine derivatives as monoamine oxidase inhibitors. Front Pharmacol 2020,10,1590","journal-title":"Front Pharmacol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"343A","DOI":"10.1097\/00002826-199201001-00178","volume":"15","author":"White H.L.","year":"1992","unstructured":"White H.L.; Ascher J.A.; Preclinical and early clinical studies with BW 1370U87, a reversible competitive MAO-A inhibitor. Clin Neuropharmacol 1992,15(Suppl. 1 Pt A),343A-344A","journal-title":"Clin Neuropharmacol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/sj.ijo.0801732","volume":"25","author":"Kilpatrick I.C.","year":"2001","unstructured":"Kilpatrick I.C.; Traut M.; Heal D.J.; Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord 2001,25(10),1454-1458","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-2012-120013","volume":"30","author":"Zheng H.","year":"2012","unstructured":"Zheng H.; Amit T.; Bar-Am O.; Fridkin M.; Youdim M.B.; Mandel S.A.; From anti-Parkinson\u2019s drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer\u2019s disease. J Alzheimers Dis 2012,30(1),1-16","journal-title":"J Alzheimers Dis"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00702-018-1861-9","volume":"125","author":"Ramsay R.R.","year":"2018","unstructured":"Ramsay R.R.; Albreht A.; Kinetics, mechanism, and inhibition of monoamine oxidase. J Neural Transm (Vienna) 2018,125(11),1659-1683","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1046\/j.1360-0443.2002.00258.x","volume":"97","author":"Berlin I.","year":"2002","unstructured":"Berlin I.; Aubin H.J.; Pedarriosse A.M.; Rames A.; Lancrenon S.; Lagrue G.; Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 2002,97(10),1347-1354","journal-title":"Addiction"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF00165029","volume":"335","author":"Keller H.H.","year":"1987","unstructured":"Keller H.H.; Kettler R.; Keller G.; Da Prada M.; Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn Schmiedebergs Arch Pharmacol 1987,335(1),12-20","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","volume":"31","author":"Blair H.A.","year":"2017","unstructured":"Blair H.A.; Dhillon S.; Safinamide: A Review in Parkinson\u2019s Disease. CNS Drugs 2017,31(2),169-176","journal-title":"CNS Drugs"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3233\/JAD-161309","volume":"58","author":"Nave S.","year":"2017","unstructured":"Nave S.; Doody R.S.; Boada M.; Grimmer T.; Savola J.M.; Delmar P.; Pauly-Evers M.; Nikolcheva T.; Czech C.; Borroni E.; Ricci B.; Dukart J.; Mannino M.; Carey T.; Moran E.; Gilaberte I.; Muelhardt N.M.; Gerlach I.; Santarelli L.; Ostrowitzki S.; Fontoura P.; Sembragiline in Moderate Alzheimer\u2019s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis 2017,58(4),1217-1228","journal-title":"J Alzheimers Dis"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1017\/jns.2016.41","volume":"5","author":"Panche A.N.","year":"2016","unstructured":"Panche A.N.; Diwan A.D.; Chandra S.R.; Flavonoids: an overview. J Nutr Sci 2016,5,e47","journal-title":"J Nutr Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.phymed.2017.12.032","volume":"40","author":"Larit F.","year":"2018","unstructured":"Larit F.; Elokely K.M.; Chaurasiya N.D.; Benyahia S.; Nael M.A.; Le\u00f3n F.; Abu-Darwish M.S.; Efferth T.; Wang Y.H.; Belouahem-Abed D.; Benayache S.; Tekwani B.L.; Cutler S.J.; Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants. Phytomedicine 2018,40,27-36","journal-title":"Phytomedicine"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/foods9030374","volume":"9","author":"Batiha G.E.S.","year":"2020","unstructured":"Batiha G.E.S.; Beshbishy A.M.; Ikram M.; Mulla Z.S.; El-Hack M.E.A.; Taha A.E.; Algammal A.M.; Elewa Y.H.A.; The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of the Major Natural Polyphenolic Flavonoid: Quercetin. Foods 2020,9(3),374","journal-title":"Foods"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biom10010059","volume":"10","author":"Khan H.","year":"2019","unstructured":"Khan H.; Ullah H.; Aschner M.; Cheang W.S.; Akkol E.K.; Neuroprotective Effects of Quercetin in Alzheimer\u2019s Disease. Biomolecules 2019,10(1),59","journal-title":"Biomolecules"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2174\/156802612805219996","volume":"12","author":"Vi\u00f1a D.","year":"2012","unstructured":"Vi\u00f1a D.; Serra S.; Lamela M.; Delogu G.; Herbal natural products as a source of monoamine oxidase inhibitors: a review. Curr Top Med Chem 2012,12(20),2131-2144","journal-title":"Curr Top Med Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2222-1808(14)60509-0","volume":"4","author":"Okhuarobo A.","year":"2014","unstructured":"Okhuarobo A.; Falodun J.E.; Erharuyi O.; Imieje V.; Falodun A.; Langer P.; Harnessing the medicinal properties of Andrographis paniculata for diseases and beyond: a review of its phytochemistry and pharmacology. Asian Pac J Trop Dis 2014,4,213-222","journal-title":"Asian Pac J Trop Dis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1541-4337.2008.00047.x","volume":"7","author":"Masibo M.","year":"2008","unstructured":"Masibo M.; He Q.; Major mango polyphenols and their potential significance to human health. Compr Rev Food Sci Food Saf 2008,7(4),309-319","journal-title":"Compr Rev Food Sci Food Saf"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/biof.5520310307","volume":"31","author":"Panda S.","year":"2007","unstructured":"Panda S.; Kar A.; Antidiabetic and antioxidative effects of Annona squamosa leaves are possibly mediated through quercetin-3-O-glucoside. Biofactors 2007,31(3-4),201-210","journal-title":"Biofactors"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1021\/np060015w","volume":"69","author":"Chimenti F.","year":"2006","unstructured":"Chimenti F.; Cottiglia F.; Bonsignore L.; Casu L.; Casu M.; Floris C.; Secci D.; Bolasco A.; Chimenti P.; Granese A.; Befani O.; Turini P.; Alcaro S.; Ortuso F.; Trombetta G.; Loizzo A.; Guarino I.; Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J Nat Prod 2006,69(6),945-949","journal-title":"J Nat Prod"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jep.2008.10.012","volume":"121","author":"Saaby L.","year":"2009","unstructured":"Saaby L.; Rasmussen H.B.; J\u00e4ger A.K.; MAO-A inhibitory activity of quercetin from Calluna vulgaris (L.) Hull. J Ethnopharmacol 2009,121(1),178-181","journal-title":"J Ethnopharmacol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/molecules24122277","volume":"24","author":"Imran M.","year":"2019","unstructured":"Imran M.; Salehi B.; Sharifi-Rad J.; Aslam Gondal T.; Saeed F.; Imran A.; Shahbaz M.; Tsouh Fokou P.V.; Umair Arshad M.; Khan H.; Guerreiro S.G.; Martins N.; Estevinho L.M.; Kaempferol: A key emphasis to Its anticancer potential. Molecules 2019,24(12),2277","journal-title":"Molecules"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/BF02861314","volume":"11","author":"Ryu S.Y.","year":"1988","unstructured":"Ryu S.Y.; Han Y.N.; Han B.H.; Monoamine oxidase-A inhibitors from medicinal plants. Arch Pharm Res 1988,11,230-239","journal-title":"Arch Pharm Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/BF02857780","volume":"10","author":"Han Y.N.","year":"1987","unstructured":"Han Y.N.; Noh D.B.; Han D.S.; Studies on the monoamine oxidase inhibitors of medicinal plants I. Isolation of MAO-B inhibitors from Chrysanthemum indicum. Arch Pharm Res 1987,10,142","journal-title":"Arch Pharm Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/molecules24030418","volume":"24","author":"Dhiman P.","year":"2019","unstructured":"Dhiman P.; Malik N.; Sobarzo-S\u00e1nchez E.; Uriarte E.; Khatkar A.; Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders. Molecules 2019,24(3),418","journal-title":"Molecules"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jep.2005.03.017","volume":"100","author":"Hou W.C.","year":"2005","unstructured":"Hou W.C.; Lin R.D.; Chen C.T.; Lee M.H.; Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla. J Ethnopharmacol 2005,100(1-2),216-220","journal-title":"J Ethnopharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijbiomac.2020.02.144","volume":"151","author":"Oh J.M.","year":"2020","unstructured":"Oh J.M.; Jang H.J.; Kim W.J.; Kang M.G.; Baek S.C.; Lee J.P.; Park D.; Oh S.R.; Kim H.; Calycosin and 8-O-methylretusin isolated from Maackia amurensis as potent and selective reversible inhibitors of human monoamine oxidase-B. Int J Biol Macromol 2020,151,441-448","journal-title":"Int J Biol Macromol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/BF02977714","volume":"28","author":"Hwang J.S.","year":"2005","unstructured":"Hwang J.S.; Lee S.A.; Hong S.S.; Lee K.S.; Lee M.K.; Hwang B.Y.; Ro J.S.; Monoamine oxidase inhibitory components from the roots of Sophora flavescens. Arch Pharm Res 2005,28(2),190-194","journal-title":"Arch Pharm Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF02977772","volume":"30","author":"Han X.H.","year":"2007","unstructured":"Han X.H.; Hong S.S.; Hwang J.S.; Lee M.K.; Hwang B.Y.; Ro J.S.; Monoamine oxidase inhibitory components from Cayratia japonica. Arch Pharm Res 2007,30(1),13-17","journal-title":"Arch Pharm Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.phytochem.2004.06.025","volume":"65","author":"Haraguchi H.","year":"2004","unstructured":"Haraguchi H.; Tanaka Y.; Kabbash A.; Fujioka T.; Ishizu T.; Yagi A.; Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry 2004,65(15),2255-2260","journal-title":"Phytochemistry"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3390\/molecules25092257","volume":"25","author":"Zarmouh N.O.","year":"2020","unstructured":"Zarmouh N.O.; Messeha S.S.; Mateeva N.; Gangapuram M.; Flowers K.; Eyunni S.V.K.; Zhang W.; Redda K.K.; Soliman K.F.A.; The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells. Molecules 2020,25(9),2257","journal-title":"Molecules"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1934578X1701200411","volume":"12","author":"Recalde-Gil M.A.","year":"2017","unstructured":"Recalde-Gil M.A.; Klein-J\u00fanior L.C.; Passos C.D.S.; Salton J.; Bordignon S.A.L.; Monace F.D.; Cechinel V.; Teresinha Henriquesa A.; Monoamine Oxidase Inhibitory Activity of Biflavonoids from Branches of Garcinia gardneriana (Clusiaceae). Nat Prod Commun 2017,12(4),505-508","journal-title":"Nat Prod Commun"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ijbiomac.2017.01.080","volume":"97","author":"Lee H.W.","year":"2017","unstructured":"Lee H.W.; Ryu H.W.; Kang M.G.; Park D.; Lee H.; Shin H.M.; Oh S.R.; Kim H.; Potent inhibition of monoamine oxidase A by decursin from Angelica gigas Nakai and by wogonin from Scutellaria baicalensis Georgi. Int J Biol Macromol 2017,97,598-605","journal-title":"Int J Biol Macromol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bioorg.2018.10.051","volume":"83","author":"Baek S.C.","year":"2019","unstructured":"Baek S.C.; Park M.H.; Ryu H.W.; Lee J.P.; Kang M.G.; Park D.; Park C.M.; Oh S.R.; Kim H.; Rhamnocitrin isolated from Prunus padus var. seoulensis: A potent and selective reversible inhibitor of human monoamine oxidase A. Bioorg Chem 2019,83,317-325","journal-title":"Bioorg Chem"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"91","DOI":"10.31254\/jahm.2015.1307","volume":"1","author":"Girdhar S.","year":"2015","unstructured":"Girdhar S.; Girdhar A.; Verma S.K.; Lather V.; Pandita D.; Plant derived alkaloids in major neurodegenerative diseases: from animal models to clinical trials. J Ayu Herb Med 2015,1,91-100","journal-title":"J Ayu Herb Med"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/ijbs.23247","volume":"14","author":"Hussain G.","year":"2018","unstructured":"Hussain G.; Rasul A.; Anwar H.; Aziz N.; Razzaq A.; Wei W.; Ali M.; Li J.; Li X.; Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders. Int J Biol Sci 2018,14(3),341-357","journal-title":"Int J Biol Sci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2174\/092986707779940998","volume":"14","author":"Cao R.","year":"2007","unstructured":"Cao R.; Peng W.; Wang Z.; Xu A.; \u03b2-Carboline alkaloids: biochemical and pharmacological functions. Curr Med Chem 2007,14(4),479-500","journal-title":"Curr Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.fct.2009.12.019","volume":"48","author":"Herraiz T.","year":"2010","unstructured":"Herraiz T.; Gonz\u00e1lez D.; Anc\u00edn-Azpilicueta C.; Ar\u00e1n V.J.; Guill\u00e9n H.; beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 2010,48(3),839-845","journal-title":"Food Chem Toxicol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jep.2004.01.013","volume":"91","author":"Kong L.D.","year":"2004","unstructured":"Kong L.D.; Cheng C.H.; Tan R.X.; Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J Ethnopharmacol 2004,91(2-3),351-355","journal-title":"J Ethnopharmacol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jep.2009.10.030","volume":"127","author":"Samoylenko V.","year":"2010","unstructured":"Samoylenko V.; Rahman M.M.; Tekwani B.L.; Tripathi L.M.; Wang Y.H.; Khan S.I.; Khan I.A.; Miller L.S.; Joshi V.C.; Muhammad I.; Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson\u2019s disease. J Ethnopharmacol 2010,127(2),357-367","journal-title":"J Ethnopharmacol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3109\/14756366.2012.666536","volume":"28","author":"Dos Santos Passos C.","year":"2013","unstructured":"Dos Santos Passos C.; Soldi T.C.; Torres Abib R.; Anders Apel M.; Sim\u00f5es-Pires C.; Marcourt L.; Gottfried C.; Henriques A.T.; Monoamine oxidase inhibition by monoterpene indole alkaloids and fractions obtained from Psychotria suterella and Psychotria laciniata. J Enzyme Inhib Med Chem 2013,28(3),611-618","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-2001-10874","volume":"67","author":"Kong L.D.","year":"2001","unstructured":"Kong L.D.; Cheng C.H.; Tan R.X.; Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med 2001,67(1),74-76","journal-title":"Planta Med"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0024-3205(01)01437-0","volume":"70","author":"Ro J.S.","year":"2001","unstructured":"Ro J.S.; Lee S.S.; Lee K.S.; Lee M.K.; Inhibition of type A monoamine oxidase by coptisine in mouse brain. Life Sci 2001,70(6),639-645","journal-title":"Life Sci"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/BF02980210","volume":"30","author":"Han X.H.","year":"2007","unstructured":"Han X.H.; Hong S.S.; Lee D.; Lee J.J.; Lee M.S.; Moon D.C.; Han K.; Oh K.W.; Lee M.K.; Ro J.S.; Hwang B.Y.; Quinolone alkaloids from evodiae fructus and their inhibitory effects on monoamine oxidase. Arch Pharm Res 2007,30(4),397-401","journal-title":"Arch Pharm Res"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s12272-001-1212-7","volume":"31","author":"Lee S.A.","year":"2008","unstructured":"Lee S.A.; Hwang J.S.; Han X.H.; Lee C.; Lee M.H.; Choe S.G.; Hong S.S.; Lee D.; Lee M.K.; Hwang B.Y.; Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidase. Arch Pharm Res 2008,31(6),679-683","journal-title":"Arch Pharm Res"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.1016\/j.bmcl.2012.09.056","volume":"22","author":"Al-Baghdadi O.B.","year":"2012","unstructured":"Al-Baghdadi O.B.; Prater N.I.; Van der Schyf C.J.; Geldenhuys W.J.; Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson\u2019s disease. Bioorg Med Chem Lett 2012,22(23),7183-7188","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.bmcl.2018.06.023","volume":"28","author":"Baek S.C.","year":"2018","unstructured":"Baek S.C.; Ryu H.W.; Kang M.G.; Lee H.; Park D.; Cho M.L.; Oh S.R.; Kim H.; Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid. Bioorg Med Chem Lett 2018,28(14),2403-2407","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1572-557X(05)02016-7","volume":"2","author":"Diderot NT","year":"2006","unstructured":"Diderot NT; Etienne NST; Xanthones as therapeutic agents: chemistry and pharmacology. Advances phytomed 2006,2,273-298","journal-title":"Advances phytomed"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1568007033482959","volume":"2","author":"Di Matteo V.","year":"2003","unstructured":"Di Matteo V.; Esposito E.; Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2003,2(2),95-107","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0031-9422(00)89727-7","volume":"36","author":"Rocha L.","year":"1994","unstructured":"Rocha L.; Marston A.; Kaplan M.A.C.; Stoeckli-Evans H.; Thull U.; Testa B.; Hostettmann K.; An antifungal gamma-pyrone and xanthones with monoamine oxidase inhibitory activity from Hypericum brasiliense. Phytochemistry 1994,36(6),1381-1385","journal-title":"Phytochemistry"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/np070690l","volume":"71","author":"Urbain A.","year":"2008","unstructured":"Urbain A.; Marston A.; Grilo L.S.; Bravo J.; Purev O.; Purevsuren B.; Batsuren D.; Reist M.; Carrupt P.A.; Hostettmann K.; Xanthones from Gentianella amarella ssp. acuta with acetylcholinesterase and monoamine oxidase inhibitory activities. J Nat Prod 2008,71(5),895-897","journal-title":"J Nat Prod"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/cmdc.201900717","volume":"15","author":"Kuder K.J.","year":"2020","unstructured":"Kuder K.J.; Za\u0142uski M.; Schabikowski J.; Latacz G.; Olejarz-Maciej A.; Ja\u015bko P.; Doroz-P\u0142onka A.; Brockmann A.; M\u00fcller C.E.; Kie\u0107-Kononowicz K.; Kie\u0107Kononowicz K. Novel, dual target-directed annelated xanthine derivatives acting on adenosine receptors and monoamine oxidase B. ChemMedChem 2020,15(9),772-786","journal-title":"ChemMedChem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1522-2675(20010321)84:3<552::AID-HLCA552>3.0.CO;2-X","volume":"84","author":"Gnerre C.","year":"2001","unstructured":"Gnerre C.; Thull U.; Gaillard P.; Carrupt P.A.; Testa B.; Fernandes E.; Silva F.; Pinto M.; Pinto M.M.M.; Wolfender J.L.; Hostettmann K.; Cruciani G.; Natural and Synthetic Xanthones as Monoamine Oxidase Inhibitors: Biological Assay and 3D-QSAR. Helv Chim Acta 2001,84,552-570","journal-title":"Helv Chim Acta"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/cbdv.200490064","volume":"1","author":"Br\u00fchlmann C.","year":"2004","unstructured":"Br\u00fchlmann C.; Marston A.; Hostettmann K.; Carrupt P.A.; Testa B.; Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chem Biodivers 2004,1(6),819-829","journal-title":"Chem Biodivers"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.5504\/BBEQ.2011.0099","volume":"25","author":"Dimitrov M.","year":"2011","unstructured":"Dimitrov M.; Nikolova I.; Benbasat N.; Kitanov G.; Danchev N.; Acute toxicity, antidepressive and MAO inhibitory activity of mangiferin isolated from Hypericum aucheri. Biotechnol Biotechnol Equip 2011,25,2668-2671","journal-title":"Biotechnol Biotechnol Equip"},{"key":"ref=168","first-page":"1317","volume":"19","author":"Singh M.","year":"2019","unstructured":"Singh M.; Saini B.; Singh T.G.; Chander J.; Satija S.; Arora S.; Design, synthesis and biological evaluation of chalcone based compounds in Alzheimer\u2019s disease. Plant Arch 2019,19(2),1317-1322","journal-title":"Plant Arch"},{"key":"ref=169","first-page":"3812","volume":"20","author":"Singh M.","year":"2020","unstructured":"Singh M.; Sharma P.; Joshi P.; Saini K.; Sharma A.; Puri V.; Chander J.; Singh T.G.; Arora S.; Chalcones: A Privileged Scaffold with Diverse Biological Activities. Plant Arch 2020,20(1),3812-3819","journal-title":"Plant Arch"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"963248","DOI":"10.1155\/2013\/963248","volume":"2013","author":"Venugopala K.N.","year":"2013","unstructured":"Venugopala K.N.; Rashmi V.; Odhav B.; Review on natural coumarin lead compounds for their pharmacological activity. BioMed Res Int 2013,2013,963248","journal-title":"BioMed Res Int"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13065-018-0497-z","volume":"12","author":"Yusufzai S.K.","year":"2018","unstructured":"Yusufzai S.K.; Khan M.S.; Sulaiman O.; Osman H.; Lamjin D.N.; Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A\/B and \u03b2-amyloid inhibitors for Alzheimer\u2019s disease. Chem Cent J 2018,12(1),128","journal-title":"Chem Cent J"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/BF02969302","volume":"29","author":"Jeong S.H.","year":"2006","unstructured":"Jeong S.H.; Han X.H.; Hong S.S.; Hwang J.S.; Hwang J.H.; Lee D.; Lee M.K.; Ro J.S.; Hwang B.Y.; Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus. Arch Pharm Res 2006,29(12),1119-1124","journal-title":"Arch Pharm Res"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bmcl.2014.12.034","volume":"25","author":"Huang M.","year":"2015","unstructured":"Huang M.; Xie S.S.; Jiang N.; Lan J.S.; Kong L.Y.; Wang X.B.; Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-\u03b2-amyloid (A\u03b2) aggregation and metal chelation properties against Alzheimer\u2019s disease. Bioorg Med Chem Lett 2015,25(3),508-513","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/s-2002-20056","volume":"68","author":"Jo Y.S.","year":"2002","unstructured":"Jo Y.S.; Huong D.T.L.; Bae K.; Lee M.K.; Kim Y.H.; Monoamine oxidase inhibitory coumarin from Zanthoxylum schinifolium. Planta Med 2002,68(1),84-85","journal-title":"Planta Med"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1515\/znc-2019-0227","volume":"75","author":"Aydin T.","year":"2020","unstructured":"Aydin T.; Akincioglu H.; Gumustas M.; Gulcin I.; Kazaz C.; Cakir A.; human monoamine oxidase (hMAO) A and hMAO B inhibitors from Artemisia dracunculus L. herniarin and skimmin: human mononamine oxidase A and B inhibitors from A. dracunculus L. Z Natforsch C J Biosci 2020,75(11-12),459-466","journal-title":"Z Natforsch C J Biosci"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450122666210707120256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194563\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450122666210707120256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:04:40Z","timestamp":1660716280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194563\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":175,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450122666210707120256","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}